CLASS ACTION UPDATE for IGT, USB and NEO: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

[ACCESSWIRE]

NEW YORK, NY / ACCESSWIRE / December 9, 2022 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.

IGT Shareholders Click Here: https://www.zlk.com/pslra-1/igt-lawsuit-submission-form?prid=34442&wire=1
USB Shareholders Click Here: https://www.zlk.com/pslra-1/u-s-bancorp-class-action-submission-form?prid=34442&wire=1
NEO Shareholders Click Here: https://www.zlk.com/pslra-1/neogenomics-lawsuit-submission-form?prid=34442&wire=1

* ADDITIONAL INFORMATION BELOW *

International Game Technology PLC (NYSE:IGT)

IGT Lawsuit on behalf of: investors who purchased March 16, 2018 - August 29, 2022
Lead Plaintiff Deadline : December 13, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/igt-lawsuit-submission-form?prid=34442&wire=1

According to the filed complaint, during the class period, International Game Technology PLC made materially false and/or misleading statements and/or failed to disclose that: (i) IGT overstated its compliance with gaming and lottery laws and applicable regulations; (ii) IGT and/or one or more of its current and/or former subsidiaries engaged in illegal gambling operations; (iii) the foregoing conduct subjected the Company and/or its current and/or former subsidiaries to a heightened risk of litigation and significant related costs; (iv) the Company downplayed the full scope and severity of its financial exposure to, and/or liabilities in connection with, the lawsuit filed against IGT's subsidiary in April of 2018; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times.

U.S. Bancorp (NYSE:USB)

USB Lawsuit on behalf of: investors who purchased August 1, 2019 - July 28, 2022
Lead Plaintiff Deadline : December 27, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/u-s-bancorp-class-action-submission-form?prid=34442&wire=1

According to the filed complaint, during the class period, U.S. Bancorp made materially false and/or misleading statements and/or failed to disclose that: (a) U.S. Bank created sales pressure on its employees that led them to open credit cards, lines of credit, and deposit accounts without consumers' knowledge and consent; (b) since at least 2015, U.S. Bank and by extension, U.S. Bancorp, was aware of such unauthorized conduct and that it was violating relevant regulations and laws aimed at protecting its consumers; (c) U.S. Bancorp failed to properly monitor its employees from engaging in such unlawful conduct, detect and stop the misconduct, and identify and remediate harmed consumers; (d) all the foregoing subjected the Company to a foreseeable risk of heightened regulatory scrutiny or investigation; (e) U.S. Bancorp's revenues were in part the product of unlawful conduct and thus unsustainable; and (f) as a result, the Company's public statements were materially false and misleading at all relevant times.

NeoGenomics, Inc. (NASDAQ:NEO)

NEO Lawsuit on behalf of: investors who purchased February 27, 2020 - April 26, 2022
Lead Plaintiff Deadline : February 6, 2023
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/neogenomics-lawsuit-submission-form?prid=34442&wire=1

According to the filed complaint, during the class period, NeoGenomics, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) defendants represented to investors that it had a "comprehensive menu" of cancer tests with "every kind of testing modality that you can use for cancer, including some of the fast-growing new ones, like next-generation sequencing," which positioned the Company as a "one-stop-shop" for pathologists and gave NeoGenomics "a competitive advantage" as a "go-to reference lab with a comprehensive menu for just about any kind of tests that you want to have done in cancer"; and (2) defendants represented that NeoGenomics could "leverage" the supposedly "fixed cost" structure of its business to improve profitability as revenue increased and touted the Company's "robust Compliance Program . . . to ensure compliance with the myriad of . . . laws, regulations and governmental guidance applicable to our business."

You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Eduard Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY 10006
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP